Amphastar Pharmaceuticals, Inc.
Balance Sheet
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $170.2M | $151.6M | $144.3M | $156.1M | $126.4M | $92.6M | $73.7M | $86.3M |
| Accounts Receivable | $143.6M | $136.3M | $114.9M | $88.8M | $78.8M | $66.0M | $45.4M | $52.2M |
| Inventory | $176.9M | $153.7M | $105.8M | $103.6M | $92.8M | $96.8M | $110.5M | $69.3M |
| Total Current Assets | $636.0M | $534.1M | $489.6M | $378.3M | $318.1M | $279.7M | $255.2M | $220.3M |
| Property, Plant & Equipment | $310.6M | $297.3M | $282.7M | $238.3M | $244.2M | $260.1M | $233.9M | $210.4M |
| Goodwill | $3.4M | $3.0M | $3.2M | $3.1M | $3.3M | $3.9M | $3.6M | $4.0M |
| Intangible Assets (Excl. Goodwill) | $533.3M | $558.4M | $580.9M | $4.9M | $6.3M | $7.5M | $8.3M | $9.1M |
| Total Assets | $1.63B | $1.58B | $1.51B | $742.0M | $671.5M | $631.2M | $587.0M | $513.6M |
| Liabilities | ||||||||
| Accounts Payable | $32.6M | $30.5M | $25.4M | $20.5M | $22.2M | $24.4M | $25.1M | $31.3M |
| Total Current Liabilities | $158.2M | $173.8M | $225.4M | $94.9M | $103.8M | $112.2M | $90.0M | $106.8M |
| Long-Term Debt | $619.7M | $613.5M | $603.2M | $76.6M | $78.2M | $45.9M | $46.3M | $49.1M |
| Total Liabilities | $840.5M | $845.2M | $873.5M | $213.3M | $226.0M | $182.5M | $159.4M | $149.2M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $666.9M | $568.8M | $409.3M | $271.7M | $180.3M | $117.8M | $116.4M | $67.5M |
| Total Stockholders' Equity | $788.8M | $732.3M | $639.4M | $528.7M | $445.5M | $402.3M | $381.4M | $332.4M |